Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847732 | 1.00 | NR1H2 (0.37) | NR1H2EPHX2 | |
| SCHEMBL963000 | 0.87 | NR1H2 (0.34) | NR1H2 | |
| SCHEMBL1543505 | 0.86 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL2105244 | 0.86 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL2104469 | 0.86 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL2104467 | 0.86 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL2104471 | 0.86 | NR1H2 (0.30) | NR1H2 | |
| SCHEMBL16296272 | 0.85 | — | — | |
| SCHEMBL16296275 | 0.85 | — | — | |
| SCHEMBL1847743 | 0.83 | GABRR1 (0.35) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193726-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2015-03-12 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | NR1H2 3084/4885EPHX2 2343/4885 |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | NR1H2 3084/4885EPHX2 2343/4885 |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | NR1H2 3011/4885EPHX2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.